XML 49 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
12 Months Ended
Jul. 31, 2023
Fair Value Measurements [Abstract]  
Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of July 31, 2023 and 2022:
   July 31, 2023 
   Level 1   Level 2   Level 3   Total 
  (in thousands) 
Assets:    
Available-for-sale securities - Corporate Bonds  $
   $46,439   $
   $46,439 
Available-for-sale securities - U.S. Treasury Bills   11,275    
    
    11,275 
Investment in equity securities   294    
    
    294 
Investment in Cyclo Therapeutics Inc. - Common stock   3,898    
    
    3,898 
Investment in Cyclo Therapeutics Inc. - Warrants   865    
    
    865 
Hedge funds   
    
    4,984    4,984 
Convertible note receivable, related party   
    
    1,921    1,921 
Total  $16,332   $46,439   $6,905   $69,676 

 

   July 31, 2022 
   Level 1   Level 2   Level 3   Total 
  (in thousands) 
Assets:    
Available-for-sale securities - Corporate Bonds  $
   $36,698   $
   $36,698 
Hedge funds   
    
    4,764    4,764 
Total  $
   $36,698   $4,764   $41,462 
Schedule of Changes in the Fair Value of the Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
   Year Ended July 31, 
   2023   2022 
   (in thousands) 
Balance, beginning of period  $4,764   $5,268 
Total gain (loss) included in earnings   220    (504)
Convertible note receivable, related party   2,000    
 
Total loss included in other comprehensive loss   (79)   
 
Balance, end of period  $6,905   $4,764